Cargando…
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab
Trastuzumab plus chemotherapy is the standard of care for the first-line treatment of patients with HER2+ advanced esophagogastric (EG) cancer. Nevertheless, patients frequently develop resistance. In preclinical models, we identified the overexpression of Fibroblast Growth Factor Receptor (FGFR) 3...
Autores principales: | Zecchetto, Camilla, Quinzii, Alberto, Casalino, Simona, Gaule, Marina, Pesoni, Camilla, Merz, Valeria, Pietrobono, Silvia, Mangiameli, Domenico, Pasquato, Martina, Milleri, Stefano, Giacopuzzi, Simone, Bencivenga, Maria, Tomezzoli, Anna, de Manzoni, Giovanni, Melisi, Davide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051335/ https://www.ncbi.nlm.nih.gov/pubmed/36983691 http://dx.doi.org/10.3390/jpm13030508 |
Ejemplares similares
-
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
por: Merz, Valeria, et al.
Publicado: (2020) -
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
por: Merz, Valeria, et al.
Publicado: (2022) -
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
por: Gaule, Marina, et al.
Publicado: (2022) -
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
por: Merz, Valeria, et al.
Publicado: (2021) -
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer
por: Bencivenga, Maria, et al.
Publicado: (2023)